Franz Obermayr, Ph.D., Acting Chief Executive Officer
Franz was previously the Co-Founder and CEO of Panoptes Pharma, a privately held biotech company, which was acquired by EyeGate in 2020. Before joining the management team at EyeGate, Dr. Obermayr had a major role in the development, clinical milestones and regulatory strategic efforts for the Company’s transformative asset, PP-001, which has two novel formulations (PaniJect and PaniDrop). Prior to Panoptes, Dr. Obermayr was Head of Clinical Development at Nabriva Therapeutics AG, where he was responsible for all clinical programs – including Xenleta (Levamulin), which was approved by the U.S. Food and Drug Administration (FDA) for community-acquired bacterial pneumonia in 2019. His earlier career involved various positions at GPC-Biotech, most recently as Director Drug Discovery. He also played a key role in the commercialization of these programs by managing large collaborations with pharmaceutical companies. Prior to GPC-Biotech, he completed his postdoctoral studies at the Max-Planck Institute for Immunobiology in Freiburg. Dr. Obermayr earned his Ph.D. in biochemistry at the Imperial Cancer Research Fund in London.
Sarah Romano, Chief Financial Officer
Sarah joined EyeGate Pharmaceuticals as Corporate Controller in 2016 and was appointed CFO in January 2018. Since joining the Company, she has been responsible for the Company’s accounting, tax, financial reporting, and internal controls. Prior to joining EyeGate, Ms. Romano served as Assistant Controller at TechTarget and Corporate Controller at Bowdoin Group, a healthcare-focused executive recruiting firm. Previously, she held financial reporting positions of increasing responsibility at SoundBite Communications until its acquisition by Genesys in 2013, and was a Senior Financial Reporting Analyst at Cognex Corporation, a publicly-traded manufacturer of machine vision systems, software and sensors. Ms. Romano began her career as an Auditor in the Boston office of PricewaterhouseCoopers. A licensed CPA in Massachusetts, she holds a Bachelor of Arts in Accounting from College of the Holy Cross and Masters of Accounting from Boston College.
Michael Manzo, Vice President of Engineering
Michael joined EyeGate in October 2006 and has served in his current role since 2008. Mr. Manzo has over 30 years of experience in product development and manufacturing in the medical device industry. Prior to joining Eyegate, Mr. Manzo was President and Chief Operating Officer (2002 – 2006) at Jenline Industries, Ltd., which is now part of Helix Medical, LLC. He has also worked with a number of start-up companies in areas such as cardiology, radiology, urology and laproscopic surgery. Mr. Manzo holds an MBA from Suffolk University and a Bachelor of Science Degree in engineering from University of Massachusetts, Lowell.
Brenda Mann, Ph.D., Vice President of R&D
Brenda has extensive experience with hydrogels for wound healing and drug delivery applications. She is a co-founder of SentrX Animal Care, focused on veterinary biomaterials and manufacturer of the CMHA-S material. She is an adjunct associate professor in the Department of Bioengineering at the University of Utah. She was a founding faculty member of the Keck Graduate Institute of Applied Life Sciences, and now serves on its Advisory Council. Dr. Mann is also the Director of the Salt Lake Valley Science and Engineering Fair and a registered patent agent.
Lisa Brandano, Vice President of Clinical Operations
Lisa joined the Company from Cato Research (CATO) where she served as Assistant Managing Director of their Boston Office and Director of Clinical Trial Operations. She was involved in the oversight and facilitation of global clinical operations. Her Clinical Research experience includes monitoring and project management of various neurology, hematology, and cardiovascular gene therapy studies spanning Phases 1, 2, and 3. Prior to this she held clinical research coordinator and laboratory science roles at Beth Israel Deaconess Medical Center in Boston. She holds a BS in biology from Emmanuel College, and since 2003, she has been a certified clinical research associate (CRA) with the Association of Clinical Research Professionals (ACRP).
Stephen From, Executive Chairman
Stephen transitioned to the role of Executive Chairman in early 2021, post the acquisition of Panoptes Pharma and previously served as EyeGate’s President, Chief Executive Officer, and director since October 2005. Prior to joining EyeGate, he was the Chief Financial Officer at Centelion SAS, an independent biotechnology subsidiary of Sanofi-Aventis. Previously, Mr. From spent several years as an investment banker specializing in the biotechnology and medical device sectors as Director in the Global Healthcare Corporate and Investment Banking Group and Head of European Life Sciences for Bank of America Securities. Mr. From holds a BSc from the University of Western Ontario, an accounting diploma from Wilfred Laurier University and has qualified as a Chartered Accountant in Ontario, Canada.